| Company Name: | Uroplasty, Incorporated | | Ticker Symbol: | UPI | | | WWW Address: | www.uroplasty.com | | CEO: | David B. Kaysen | | No. of Employees: | 64 | | Common Issue Type: | CS | | Business Description: | A medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.09 |  0.02 | 0.19 | 2.01 | 1.09 | 1.20 | 1.09 | 28500 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 16.3 | 14.9 | 2.29 | -0.24 | 0.00 | 0.0 | 0.0 | 3.07 - 0.34 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.09 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 16.3 | mil |
| Latest Shares Outstanding | 14.9 | mil |
| Earnings pS (EPS) | -0.24 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 230,344 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 4.2 | mil |
| Float as % of Shares Outstanding | 28.2 | % |
| Foreign Sales | 7 | mil |
| Domestic Sales | 8 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 92.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 23.00 | % |
| Gross Profit Margin | 84.9 | % |
| EBITDA Margin | -30.4 | % |
| Pre-Tax Profit Margin | -39.3 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | -39.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -46.1 | % |
| Current Ratio | 5.7 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.43 | $ |
| Cash pS | 0.12 | $ |
| Book-Value pS | 0.70 | $ |
| Tangible Book-Value pS | 0.51 | $ |
| Cash Flow pS | -0.25 | $ |
| Free Cash Flow pS | -0.21 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.55 | |
| Price/Tangible Book Ratio | 2.15 | |
| Price/Cash Flow | -4.4 | |
| Price/Free Cash Flow | -5.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 99 | 161 | 381 |
| 4 Weeks | 1.35 | 1.05 | 1.45 | -24.8 | 70 | 218 | 3,710 |
| 13 Weeks | 2.50 | 0.61 | 0.65 | 67.7 | 156 | 794 | 48,453 |
| 26 Weeks | 2.50 | 0.60 | 0.88 | 23.9 | 103 | 501 | 62,643 |
| 52 Weeks | 3.07 | 0.34 | 1.29 | -15.5 | 68 | 353 | 87,885 |
| YTD | 3.07 | 0.34 | - | 14.7 | 94 | 378 | 85,789 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.10 | 1.12 | 1.29 | 0.93 | 0.84 | 2.29 | 2.40 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 19.08 | 76.0 | 22.15 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 21.74 | NA | -24.42 |
| R&D | 1.40 | NA | -1.07 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -31.2 | -23.8 | 6.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.09 | -0.02 | 0.04 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 53.38 |
| Current Ratio | 5.1 |
| Quick Ratio (Acid Test) | 4.7 |
| Liquidity Ratio (Cash) | 4.03 |
| Receivables Turnover | 8.2 |
| Average Collection Period | 44 |
| Working Capital/Equity | 63.7 |
| Working Capital pS | 0.53 |
| Cash-Flow pS | -0.16 |
| Free Cash-Flow pS | -0.11 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.64 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 16.2 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 3.6 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.13 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.79 |
| Tobin's Q Ratio | 1.11 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -4.38 |
| Enterprise Value (EV)/Free Cash Flow | -14.14 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.15 |
| Price/Book Ratio - LTM | 1.55 |
| Price/Cash Flow Ratio | -4.4 |
| Price/Free Cash Flow Ratio - LTM | -5.1 |
| Price/Sales Ratio | 1.35 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.13 |
| Tangible Book Value pS - LTM | 0.51 |
| Book Value pS - LTM | 0.70 |
| Capital Invested pS | 0.82 |
| Cash pS - LTM | 0.12 |
| Cash Flow pS - LTM | -0.25 |
| Free Cash Flow pS - LTM | -0.21 |
| Earnings pS (EPS) | -0.24 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -11.16 |
| Free Cash Flow Margin 5YEAR AVG | -35.84 |
| Net Profit Margin | -24.3 |
| Net Profit Margin - 5YEAR AVRG. | -37.5 |
| Equity Productivity | 1.20 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.20 |
| Return on Capital Invested (ROCI) | -29.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -42.8 |
| Assets Productivity | 0.90 |
| Return on Assets (ROA) | -24.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -33.4 |
| Gross Profit Margin | 84.9 |
| Gross Profit Margin - 5YEAR AVRG. | 79.6 |
| EBITDA Margin - LTM | -30.4 |
| EBIT Margin - LTM | -39.1 |
| Pre-Tax Profit Margin | -23.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -36.8 |
| Effective Tax Rate | -3.3 |
| Effective Tax Rate - 5YEAR AVRG. | -2.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 125 |
| Revenue per Employee | 230,344 |
| Net Income per Employee | -55,906 |
| Average Collection Period | 30 |
| Receivables Turnover | 8.2 |
| Day's Inventory Turnover Ratio | 95 |
| Inventory Turnover | 3.8 |
| Inventory/Sales | 3.4 |
| Accounts Payble/Sales | 4.10 |
| Assets/Revenue | 1.11 |
| Net Working Capital Turnover | 1.88 |
| Fixed Assets Turnover | 3.00 |
| Total Assets Turnover | 0.9 |
| Revenue per $ Cash | 4.50 |
| Revenue per $ Plant | 10.52 |
| Revenue per $ Common Equity | 1.20 |
| Revenue per $ Capital Invested | 1.20 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 86.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 88.4 |
| Research & Devlopment (R&D) as % of Revenue | 17.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 17.3 |
|
|  
|
| |
 |  |